Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 30 vs SUSTAIRE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
FDA-approved for maintenance treatment of asthma in patients aged 6 years and older,FDA-approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults,Off-label: acute asthma exacerbations (as part of SMART therapy)
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
50 mg orally twice daily
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Terminal elimination half-life of 8-12 hours in healthy adults; prolonged in renal impairment.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Budesonide: extensively metabolized in the liver via CYP3A4 to inactive metabolites; formoterol: partially metabolized via glucuronidation and O-demethylation, with minor CYP involvement.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Primarily renal excretion (80-90% unchanged); minor biliary/fecal elimination (10-20%).
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Approximately 95% bound to albumin.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
0.2-0.3 L/kg; indicates limited extravascular distribution primarily in plasma and interstitial fluid.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
Oral: 70-80% due to first-pass metabolism; intravenous: 100%.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
GFR 30-59 m L/min: 50 mg once daily; GFR 15-29 m L/min: 25 mg once daily; GFR <15 m L/min: not recommended
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Child-Pugh A: 50 mg twice daily; Child-Pugh B: 25 mg twice daily; Child-Pugh C: 12.5 mg once daily
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Weight-based: 0.5 mg/kg orally twice daily, max 25 mg per dose
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
Age >65 years: initiate at 25 mg twice daily; monitor renal function
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. SUSTAIRE is contraindicated for use as primary therapy for acute asthma exacerbations. For asthma, use only as add-on therapy for patients not adequately controlled on low-to-medium dose inhaled corticosteroids (ICS) or whose disease severity warrants initiation of ICS and LABA.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
LABA-associated asthma-related death; cardiovascular effects (tachycardia, hypertension); paradoxical bronchospasm; hypokalemia; hyperglycemia; increased susceptibility to infections; adrenal insufficiency with systemic steroid withdrawal; acute asthma exacerbation management.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Primary treatment of status asthmaticus or acute asthma exacerbations; severe hypersensitivity to any ingredient.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
No significant food interactions. Grapefruit or grapefruit juice may increase systemic exposure; avoid excessive consumption. No specific dietary restrictions required.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, hypotonia, and withdrawal syndrome with chronic use. Avoid use unless benefit outweighs risk.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Excreted in breast milk; M/P ratio approximately 0.24. Limited data suggests low infant dose (0.5-1% maternal weight-adjusted dose). Monitor infant for drowsiness and feeding difficulties. Consider risk-benefit.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
No standard dose adjustment recommended. Increased plasma volume may reduce drug levels; monitor clinical response. Avoid near term due to risk of neonatal depression. Use lowest effective dose for shortest duration.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
SUSTAIRE is an inhaled corticosteroid (ICS) used for maintenance treatment of asthma. It is not indicated for acute bronchospasm. Rinse mouth with water after each use to prevent oral candidiasis. Titrate to lowest effective dose to minimize systemic effects. Monitor for growth suppression in children and adrenal insufficiency during stress or prolonged use.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
Use SUSTAIRE regularly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking SUSTAIRE without consulting your doctor, even if you feel better.,Keep track of your symptoms and peak flow if advised.,Seek medical help if your rescue inhaler is not working or you need more puffs than usual.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 30 vs SUSTAIRE, answered by our medical review team.
ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. SUSTAIRE is a Methylxanthine Bronchodilator that works by SUSTAIRE (budesonide/formoterol) is a fixed-dose combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-adrenergic agonist (formoterol). Budesonide exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory mediator release, and reducing airway hyperresponsiveness. Formoterol selectively activates beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation via increased c AMP production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 30 and SUSTAIRE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. The standard adult dose of SUSTAIRE is: 50 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 30 and SUSTAIRE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. SUSTAIRE is classified as Category C. Pregnancy Category C. First trimester: risk of major malformations unknown, but animal studies show fetal harm. Second/third trimester: potential for fetal respiratory depression, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.